nidНефрология и диализNephrology and Dialysis1680-44222618-9801Российское диализное обществоnid-3751Research ArticleМАТЕРИАЛЫ III МЕЖДУНАРОДНОГО СЕМИНАРА ПО НЕФРОЛОГИИСовременные представления об анемии при почечной недостаточностиAnemia of Renal Failure - An UpdateПитерГ. БлэйкPeterG. Blakenoemail@neicon.ruОтделение нефрологии. Лондонский научный центр здоровья и Университет Западного Онтарио, Лондон, Онтарио, КанадаРоссияDivision of Nephrology. London Health Science Center, London, Ontario, CanadaRussian Federation20002806202524247251Copyright © Питер Г.Б., 20252025Питер Г.Б.Peter G.B.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephro.ru/jour/article/view/3751

Введение Внедрение в клиническую практику в конце 1980-х годов рекомбинантного эритропоэтина (Эпо) стало поворотным пунктом в лечении терминальной ХПН (ТХПН) [1]. Оно привело к улучшению качества жизни больных и, по-видимому, способствовало наблюдаемому в течение последнего десятилетия повышению их выживаемости, хотя это и вызывает некоторые сомнения. Наконец, клиническое использование Эпо открыло для нефрологического сообщества много нового относительно анемии при почечной недостаточности (ПН), значения в ее механизме воспаления и дефицита железа. * Перевод Н.А. Томилиной

ХПНанемиялечение Эпоцелевой гемоглобинзапасы железавоспалениеReferencesMacDougall I.C. Meeting the challenges of a new millennium: optimizing the use of recombinant human erythropoietin. Nephrol Dial Transplant 1998; 13: (suppl 2) S23-S27.MacDougall I.C. Meeting the challenges of a new millennium: optimizing the use of recombinant human erythropoietin. Nephrol Dial Transplant 1998; 13: (suppl 2) S23-S27.Eckardt K.U. Cardiovascular consequences of renal anaemia and erythropoietin therapy. Nephrol Dial Transplant 1999; 14: 1317-1323.Eckardt K.U. Cardiovascular consequences of renal anaemia and erythropoietin therapy. Nephrol Dial Transplant 1999; 14: 1317-1323.Foley R.N., Parfrey P.S., Harnett J.D. et al. The impact of anemia on cardiomyopathy, morbidity and mortality in end-stage renal disease. Am J Kidney Dis. 1996; 28: 53-61.Foley R.N., Parfrey P.S., Harnett J.D. et al. The impact of anemia on cardiomyopathy, morbidity and mortality in end-stage renal disease. Am J Kidney Dis. 1996; 28: 53-61.Eschbach J.W., Abdulhadi M.H., Browne J.K. et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease: results of a phase 111 multicenter clinical trial. An Int Med 1989; 111: 992-1000.Eschbach J.W., Abdulhadi M.H., Browne J.K. et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease: results of a phase 111 multicenter clinical trial. An Int Med 1989; 111: 992-1000.Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ 1993: 573-578.Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ 1993: 573-578.Bessarab A., Kline Bolton W., Browne J.K. et al. The effects of normal as compared with normal hematocrit in patients with cardiac disease who are receiving hemodialysis Epoetin. N Engi J Med 1998; 339: 584-590.Bessarab A., Kline Bolton W., Browne J.K. et al. The effects of normal as compared with normal hematocrit in patients with cardiac disease who are receiving hemodialysis Epoetin. N Engi J Med 1998; 339: 584-590.Foley R.N., Parfrey P.S., Morgan J. et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 2000; 58: 1325-1335.Foley R.N., Parfrey P.S., Morgan J. et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 2000; 58: 1325-1335.Eevin A., Thompson C.R., Athier J. et al. Left ventricular mass increase in early renal disease: Impact of decline in hemoglobin. Am J Kidney Dis 1999; 34: 125-134.Eevin A., Thompson C.R., Athier J. et al. Left ventricular mass increase in early renal disease: Impact of decline in hemoglobin. Am J Kidney Dis 1999; 34: 125-134.NKF-DOQ1 Clinical practice: Guidelines for the Treatment of Anemia of Chronic Renal Failure. New York, National Kidney Foundation, 1997.NKF-DOQ1 Clinical practice: Guidelines for the Treatment of Anemia of Chronic Renal Failure. New York, National Kidney Foundation, 1997.Toffelmire E.B., Barrett B.J., Fenton S.S. et al. Clinical practice guidelines for the management of anemia co-existent with Chronic Renal Failure. J Am Soc Nephrol 1999; 10: (suppl 13) S292-S296.Toffelmire E.B., Barrett B.J., Fenton S.S. et al. Clinical practice guidelines for the management of anemia co-existent with Chronic Renal Failure. J Am Soc Nephrol 1999; 10: (suppl 13) S292-S296.European Best Practice Guidelines for the Management of Anemia in Patients with Chronic Renal Failure. Nephrol Dial Transplant 1999; 14: (supp l5) l-50.European Best Practice Guidelines for the Management of Anemia in Patients with Chronic Renal Failure. Nephrol Dial Transplant 1999; 14: (supp l5) l-50.Obrador G.T., Ruthazer R., Arora P. Prevalence of and factors associated with suboptimal care before initiation of dialysis in the United States. J Am Soc Nephrol 1999; 10: 1793-1800.Obrador G.T., Ruthazer R., Arora P. Prevalence of and factors associated with suboptimal care before initiation of dialysis in the United States. J Am Soc Nephrol 1999; 10: 1793-1800.Fishbane S., Maesaka J.K. Iron management in end-stage renal disease. Am J Kidney Dis 1997; 29: 319-333.Fishbane S., Maesaka J.K. Iron management in end-stage renal disease. Am J Kidney Dis 1997; 29: 319-333.Perez R., Spanner E., Heidenheim A.P., Blake P.G. Prevalence and predictors of iron deficiency in a population with advanced chronic renal failure. (Abstract) J Am Soc Nephrol 2000; 1: A0402.Perez R., Spanner E., Heidenheim A.P., Blake P.G. Prevalence and predictors of iron deficiency in a population with advanced chronic renal failure. (Abstract) J Am Soc Nephrol 2000; 1: A0402.Nissenson A.R., Lindsay R.M., Swan S. et al. Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patient: North American Clinical Trial. Am J Kidney Dis 1999, 33: 471-482.Nissenson A.R., Lindsay R.M., Swan S. et al. Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patient: North American Clinical Trial. Am J Kidney Dis 1999, 33: 471-482.Silverberg D.S., laina A., Peer G. et al. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure in patients not receiving dialysis. Am J Kidney Dis 1996; 27: 234-238.Silverberg D.S., laina A., Peer G. et al. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure in patients not receiving dialysis. Am J Kidney Dis 1996; 27: 234-238.Vychytil A., Haag-Weber M. Iron status and iron supplementation in peritoneal dialysis patients. Kidney Int 1999; 55: (suppl 69) S71-S78.Vychytil A., Haag-Weber M. Iron status and iron supplementation in peritoneal dialysis patients. Kidney Int 1999; 55: (suppl 69) S71-S78.Collins A., Ebben J., Ma J. Frequent IV iron dosing is associated with higher infectious death (Abstract). J Am Soc Nephrol 1997; 8: 190A.Collins A., Ebben J., Ma J. Frequent IV iron dosing is associated with higher infectious death (Abstract). J Am Soc Nephrol 1997; 8: 190A.Silverberg D.S., Blum M., Agbraria Z. et al. Intravenous iron for the treatment ofpredialysis anemia. Kidney Int 1999; 55: (suppl 69) S79-S85.Silverberg D.S., Blum M., Agbraria Z. et al. Intravenous iron for the treatment ofpredialysis anemia. Kidney Int 1999; 55: (suppl 69) S79-S85.Stenveinkel P., Heimburger О., Lindholm B. et al. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol Dial Transplant 2000; 5: 953-960.Stenveinkel P., Heimburger О., Lindholm B. et al. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol Dial Transplant 2000; 5: 953-960.Perez R., Spanner E., Heidenheim A.P., Blake P.G. C-Reactive protein (CRP) levels and their predictors in an advanced chronic renal failure (CRF) population. (Abstract) J Am Soc Nephrol 2000; 1: A0403.Perez R., Spanner E., Heidenheim A.P., Blake P.G. C-Reactive protein (CRP) levels and their predictors in an advanced chronic renal failure (CRF) population. (Abstract) J Am Soc Nephrol 2000; 1: A0403.

The authors declare that there are no conflicts of interest present.